secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001493152-22-031235
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo Pharma Q1 FY2023 net loss $2.6M ($0.11/sh); positive ANEB-001 Phase 2 data
--------------------------------------------------------------------------------

- Net loss $2.6M vs $1.6M YoY; diluted EPS ($0.11) vs ($0.07).
- Cash $19.2M at Sept 30, 2022; cash burn $2.0M in quarter.
- Positive interim data for ANEB-001 from Phase 2 Part B announced.
- Closed $6.6M private placement financing in September 2022.
- Appointed Nat Calloway, Ph.D. to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222031235/0001493152-22-031235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222031235/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer